How Investors Are Reacting To BioCryst (BCRX) Winning Japan’s First Oral Pediatric HAE ApprovalSimplywall·Aug 27 at 03:25 AMBCRX-1.22%
BioCryst says Japan approves Orladeyo for pediatric HAE patients aged 2-11PUBT·Aug 25 at 06:03 AMBCRX-1.22%
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in JapanUnusual Whales·Aug 25 at 06:03 AMBCRX-1.22%
BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now?Simplywall·Aug 22 at 06:45 PMBCRX-1.22%
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.7% - Here's What HappenedMarket Beat·Aug 13 at 01:00 PMBCRX-1.22%
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street ZenMarket Beat·Aug 8 at 12:18 AMBCRX-1.22%
How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) InvestorsSimplywall·Aug 7 at 02:51 AMBCRX-1.22%
Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock PriceMarket Beat·Aug 6 at 12:12 PMBCRX-1.22%
Wedbush Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock PriceMarket Beat·Aug 6 at 11:24 AMBCRX-1.22%
BioCryst Pharma shares are trading higher after the company reported better-than-expected Q2 sales results.benzinga_article·Aug 5 at 06:58 AMBCRX-1.22%
BioCryst Q2 2026 earnings: Licensing revenue lifts operating profitTradingKey·Aug 5 at 06:48 AMBCRX-1.22%
BioCryst Q2 FY26 net income rises to USD 78.4 million; revenue climbs 34% to USD 218.3 millionPUBT·Aug 5 at 06:10 AMBCRX-1.22%
